You are here

Article Text

Article menu
Download PDFPDF
Consensus statement
Supplement
Documentation of off-label use of biologics in Rheumatoid Arthritis
  1. Daniel E Furst,
  2. Roy Fleischman,
  3. Joachim Kalden,
  4. Arthur Kavanaugh,
  5. Joachim Sieper,
  6. Philip Mease,
  7. Josef Smolen,
  8. Ferrie Breedveld
  1. Los Angeles, California, USA
  1. Correspondence to Daniel E Furst, 1000 Veteran Ave, Rm 32-59, Los Angeles, CA 90025, USA; gvaldivia{at}mednet.ucla.edu.

http://dx.doi.org/10.1136/annrheumdis-2013-consensusapp

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    The ‘Updated Consensus Statement on Biological Agents for the Treatment of Rheumatic Diseases’ represents the consensus and efforts of a worldwide group of experts regarding the use of biologics in Rheumatoid Arthritis. That document details the use of biologics in registered uses for those drugs.

    However, the biologic agents are used ‘off label’ in a very large array of other rheumatic diseases. To some degree, those uses are based on animal studies and mechanistic rationale but they often …

    View Full Text

    Footnotes

    • Handling editor Tore K Kvien